Iodine Status and Characteristics of Papillary Thyroid Cancer
ConditionPapillary Thyroid Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorShandong Provincial Hospital
About this trial
The effect of iodine on papillary thyroid cancer has been controversial for many years. The investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age range: 18~65 years old, gender not limited;
Living in the residential area for at least 5 years;
Patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer;
Complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc.
Disqualifiers
Pathological diagnosis of other types of thyroid cancer;
Diagnosed with other types of cancer;
There are serious comorbidities of the heart, liver, and kidneys;
Trial population
Three sub centers will be selected in high iodine areas (Jining, Liaocheng, Heze) and moderate iodine areas (Jinan, Shenyang, Harbin) respectively. People who have lived in these areas for more than 5 years and seek medical treatment in tertiary hospitals will be selected.
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Iodine excess
Dietary supplementIodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L
Iodine suitable
Dietary supplementIodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
Treatment groups
600 Participants
are divided into 2 treatment groupsGroup A: Excessive iodine group1 intervention
Group B: Suitable iodine group1 intervention
Trial outcomes
Primary outcomes
1
Serum and urine iodine levels
Time frame
1 year from enrollment2
TNM staging of papillary thyroid cancer
Time frame
3 month from enrollmentLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: